Compass Pathways (FRA:5Y6) Change In Receivables : €0.00 Mil (TTM As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Compass Pathways Change In Receivables?

Compass Pathways's change in receivables for the quarter that ended in Jun. 2024 was €0.00 Mil. It means Compass Pathways's Accounts Receivable stayed the same from Mar. 2024 to Jun. 2024 .

Compass Pathways's change in receivables for the fiscal year that ended in Dec. 2023 was €0.00 Mil. It means Compass Pathways's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Compass Pathways's Accounts Receivable for the quarter that ended in Jun. 2024 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Compass Pathways's liquidation value for the three months ended in Jun. 2024 was €163.85 Mil.

Compass Pathways Change In Receivables Historical Data

The historical data trend for Compass Pathways's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compass Pathways Change In Receivables Chart

Compass Pathways Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

Compass Pathways Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Compass Pathways Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Compass Pathways (FRA:5Y6) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Compass Pathways's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Compass Pathways's accounts receivable are only considered to be worth 75% of book value:

Compass Pathways's liquidation value for the quarter that ended in Jun. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	212.395	-	48.55	+	0.75 * 0	+	0.5 * 0
=	163.85

Compass Pathways Change In Receivables Related Terms

Thank you for viewing the detailed overview of Compass Pathways's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Compass Pathways Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Compass Pathways PLC (FRA:5Y6) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

CMPS:USA

Address

33 Broadwick Street, London, GBR, W1F 0DQ

Website

https://www.compasspathways.com

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Compass Pathways Headlines

No Headlines